



1 PRESCRIBING BLOOD COMPONENTS

Date Issued: January 2005

Date Revised: February 2009

Review Date: January 2011

Authorised by: KEMH & PMH Transfusion Committees

Review Team: KEMH & PMH Transfusion Committees

1.4 Clinical Indications for Blood Products

Section 1

Transfusion Medicine Protocols

Child & Adolescent & Women's & Newborn Health Services

Perth Western Australia

1.4 CLINICAL INDICATIONS FOR BLOOD PRODUCTS

Reference is made to The National Health and Medical Research Council (NHMRC) clinical practice guidelines on Blood and Blood Products:

The **Clinical Practice Guidelines for the use of Blood Components** aim to:

- Improve the consistency and appropriateness of transfusion practice;
- Promote the integration of quality management systems into transfusion practice;
- Reduce the overall number of transfusion-related complications;
- Increase consumer awareness of the benefits and risks of blood component therapy;
- Conserve a limited resource.

To assist clinicians to have readily available information the Working Party that developed the Guidelines, also developed a series of documents tailored to meet the needs of the clinicians. In addition, the Working Party recognised the importance of consumer issues and processes for informed consent.

Appropriate Use of Red Blood Cells

Appropriate Use of Platelets

Appropriate Use of Fresh Frozen Plasma and Cryoprecipitate

These are available at

www.nhmrc.gov.au/publications/subjects/blood.htm